



# **Susceptibility of *Escherichia coli*, *Salmonella typhi* and *Shigella* spp to Ethanolic Extract of *Lawsonia inermis***

**Paul Amos Bassi <sup>a</sup>, Manpreet Kaur <sup>b</sup>, Manavjot Kaur <sup>b</sup> and Ramyil M. S. Crown <sup>c\*</sup>**

<sup>a</sup> Department of Microbiology, Faculty of Natural Sciences, Bingham University Karu, Nigeria.

<sup>b</sup> Shaheed Udham Singh College of Research and Technology, Tangori in affiliation to Punjabi University, Patiala, Punjabi, India.

<sup>c</sup> Department of Medical Microbiology and Parasitology, College of Medicine and Health Sciences, Bingham University Jos Campus, Nigeria.

## **Authors' contributions**

This work was carried out in collaboration among all authors. Author PAB designed the study, performed the statistical analysis, wrote the protocol, and wrote the first draft of the manuscript. Authors Manpreet Kaur and Manavjot Kaur managed and reviewed the analyses of the study. Author RMSC managed the literature searches and wrote the second draft of the manuscript. All authors read and approved the final manuscript.

## **Article Information**

DOI: 10.9734/MRJI/2022/v32i330379

### **Open Peer Review History:**

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/81490>

**Original Research Article**

**Received 09 December 2021**

**Accepted 15 February 2022**

**Published 18 July 2022**

## **ABSTRACT**

**Background:** The acceptance of traditional medicine as an alternative form of healthcare and the development of microbial resistance to the available antibiotics has led researchers to investigate the antimicrobial activity of plant extracts.

**Aim:** This was to evaluate antibacterial activity and potential effect of *Lawsonia inermis* leaves against three test organisms namely: *Escherichia coli*, *Salmonella typhi*, and *Shigella*.

**Methodology:** Ethanolic extracts of *Lawsonia inermis* was obtained. The extracts were boiled, macerated, soaked and the implementation of the extracts to determine the antimicrobial activities on culture was performed by diffusion method. Three antibiotics (Gentamicin, Ciprofloxacin and Cefataxime) were used as control for the test organisms respectively.

\*Corresponding author: E-mail: crownramyil@yahoo.com;

**Results:** The inhibition of each test organism was achieved in one or two extracts. *Escherichia coli* had the highest (7.25mm) zone of inhibition from soaked extract with lowest (5.00mm) zone of inhibition from boiled extract, *Salmonella typhi* had the highest (11.63mm) zone of inhibition from boiled extract with lowest (8.25mm) zone of inhibition from macerated extract, and *Shigella* had the highest zone of inhibition 19.50mm from soaked extract, and had the lowest zone of inhibition 12.63mm from boiled extract. Furthermore, the soaked ethanoic extract had a zone of inhibition ranging from 7.25mm- 19.50mm. Also, the ethanoic extract boiled had zones of inhibition ranging from 5.00mm – 12.63mm, and the ethanoic extract macerated had a zone of inhibition range of 6.63mm- 17.75mm. The zones of inhibition produced by the controls are; gentamicin produced zones of inhibition ranging from 25.00mm – 26.00mm, ciprofloxacin produced zones of inhibition ranging from 20.00mm – 22.00mm, and cefataxime produced zones of inhibition ranging from 18.00mm – 21.00mm. The Statistical analysis was applied to the result using the one-way ANOVA test to compare the differences in the means.

**Conclusion:** The results indicated that there was no significant difference in the effects of the ethanoic extracts of *Lawsonia inermis* on the tests organisms *S. typhi*, *E. coli* and *Shigella* and the controls. ( $p < 0.05$ , F Cal = 0.103, F Tab = 4.257).

**Keywords:** *Lawsonia inermis*; traditional medicine; medicinal plants; antibacterial activity; *Escherichia coli*; *Salmonella typhi* and *Shigella*.

## 1. INTRODUCTION

The increase of multidrug resistant microorganisms is leading to the decrease in the development of new synthetic anti-microbial drugs and also the need to search of new antimicrobial sources and new alternatives [1]. The new discoveries of the efficient effect of traditional medicine as a substitute in health care, coupled with the increase of antimicrobial resistance of microorganisms to the already available and usable antibiotics has directed researchers to explore the effect of herbal medicine from traditional medicine and explore the antimicrobial effect of the herbs used in herbal medicine. Herbal and medicinal plants have since ancient times have been used to treat and combat diseases. In traditional Indian medicine and the world, there is a plethora of knowledge, information and benefits of herbal drugs or medicine where there is a great demand both in the developed and developing countries for primary healthcare because of their wide biological and medicinal activities with higher safety margins and have lesser costs [2]. The high percentage of herbal drugs used by the population of developing countries that are unable to afford, and also don't have access to pharmaceutical drugs is as high as 80%. They rely on the available tradition and herbal drugs from plants to maintain their healthcare requirements [3]. About 20% of plants found in the world had been submitted to pharmaceutical or biological tests and a sustainable number of new antibiotics introduced in the market were obtained from natural or semisynthetic resources [4]. In recent times, researchers have directed

their attention towards the observation of herbal medicines based on the hypothesis that plants contain natural and novel substances that can promote health and alleviate illnesses and also improve the quality of life. The increase of public and private interest in the application of herbal/traditional medicine and remedies even with its slow healing activity but has a more permanent cure against various diseases. Though herbal/traditional methods still play a vital role to cover the basic health needs in the developing countries and the need to explore and discover new molecular structure as lead compounds [5-7]. Microorganisms have the genetic ability to acquire and develop antimicrobial resistance which is been utilize to nullify the effect of the antimicrobial agents. Although the development of new antimicrobials are been performed, the resistance of microorganisms to these new antimicrobials is also on the rise, which has led to the search of new antimicrobial molecules that have more efficient antimicrobial effect. This is the requirement for the research of natural therapies [8,9]. Measures been taken to combat/tackle the alarming increase of antimicrobial resistance to antimicrobials caused by natural resistance of the microbes and the attitude for the use of antimicrobial agents [10]. According to WHO, medicinal plants are the greatest source to obtain a variety of drugs. The phytochemicals are the natural products and can be used in the control and cure of diseases such as Diabetes, Alzheimer, Parkinson, Arteriosclerosis etc. traditional medicine are been used and utilized by individuals from developing countries at a high

percentage of 80 which are derived from medicinal plants. This indicates the positive effect of these plants as drugs and these medicinal plants should be investigated, for better understanding of their nature and properties, safety and efficiency [11].

In rural areas of the developing countries, medicinal plants continue to be used as the primary source of medicine as traditional treatment for numerous human diseases [12]. About 75%-80% of the world's population utilize plant medicines either in part or entirely [13]. According to Kim [14] there are approximately 500,000 plant species occurring worldwide, of which only 1% diseases causing bacteria.

**Lawsonia inermis:** Henna *Lawsonia inermis*, belongs to lythraceae also known as the loosestrife family. Henna is cultivated by many farmers for cosmetic and pharmaceutical purposes, it belongs to the group of plants that are popular in nature and all parts of the plant (root, stem, leaf, flower pod and seed) are of great medicinal importance have been cultivated for traditional medicine because of its cosmetic agent and pharmacological activities worldwide [15]. Most importantly, the leaf part of the plant contained a coloring compound called Lawson which is a red orange dye molecule, also known as hennotannic acid used for dyeing the skin, hair and fingernails as well as fabrics including silk, wool and leather [16]. Apart from the dyeing properties, the *L. inermis*, normally known as *hina*, or the henna tree in English, *Mehandi* in Hindi, *Shudi* in Bengali, *Goranta* in Kannada, *Mailanschi* in Malayalam, *Padchi-methi* in Marathi, *Dvivraṅta* in Sanskrit, *Gorata* in Telugu, *Aiyanaṃ* in Tamil, *Monjathi* in Oriya, *Maduyanta* in Tibetan, the mignonette tree, and the Egyptian privet have been reported to have analgesic, hypoglycemic, hepato-protective, immune-stimulant, anti-inflammatory, antibacterial/fungal, antiviral and antiparasitic properties for the cure of renal lithiasis, jaundice, wound healing and prevention of skin inflammation and leprosy. The species is named after the Scottish physician Isaac Lawson, a good friend of Linnaeus [17,18].

### 1.1 Phytochemical Components

Phytochemicals are chemical components of plants that occur naturally and are found in the flower, buds, fruits, barks, leaves vegetables and roots. These components are utilized by plants to fight against diseases. Phytochemicals are also

found in spices and medicinal plants, they contribute to the plants color, aroma, and flavor. They are accumulated in different parts of the plants such as the roots, stems, and leaves [20,21]. These phytochemicals have been shown to show similar effects in humans against microbials and have protective and preventive effects against degenerative diseases and pathological processes such as ageing neurodegenerative disorder, atherosclerosis and inflammation [22]. Phytochemicals are categorized as primary and secondary constituents in which proteins, chlorophyll and common sugars are primary constituents while terpenoid, alkaloids, phenolic compounds are grouped into secondary constituents with various important pharmacological activities in Terpenoids, anaesthetic agents in Alkaloids [20,23,24]. The phytochemical analysis of the aqueous extract of *Lawsonia inermis* is largely studied by many practitioners of traditional herbal medicines revealed the presence of carbohydrates, phenolic compounds, flavonoids, saponins, proteins, alkaloids, terpenoids, quinones, coumarins, xanthenes, 6% fat, 2-3% resin and 7-8% tannins. *Lawsonia inermis* contained 2-hydroxy-1,4-naphthoquinone (lawsone). HPLC analysis showed that the extracts of *Lawsonia inermis* flowers, leaves and branches contained 116.9, 486.2 and 5.4 µg/g lawsone [5]. Polyphenols (equivalent to gallic acid), tannins (equivalent to catechin), flavonoids (equivalent to quercetin) and anthocyanins (equivalent to cyanidin), Other naphthoquinone derivatives: 1,3-dihydroxy naphthalene, 1,4-naphthoquinone, 1,2-dihydroxy-4-glucosylnaphthalene and 1,2,4-trihydroxynaphthalene-2-O-β-D-glucopyranoside were also isolated from the leaves of *Lawsonia inermis* [26, 27]. Henna is a whole glycosidase, able to break down the glycosidic bond when drawn in contact with hot water. Therefore lawsone has been extracted by maceration, infusion and digestion [28]. The main colouring agent of henna is lawsone (2-hydroxy-1,4 naphthoquinone) which is particularly undiffused in the leaves foliage. The dry powder leaves of henna consist of 0.5 — 1.5% lawsone. Besides lawsone, the plant also contains esculetin, Gallic acid, hennadiol, betulinic acid, hennatannic acid coumarin, laxanthone, etc [19,29,30].

### 1.2 Antimicrobial Activity

The agents/ chemicals, or solutions used in destroying, killing or inhibiting the growth of



**Fig. 1(a-b). Pictograph of Henna, (*Lawsonia inermis*)**  
(a. Source; Sarita et al. [19] (b. Source; Jeba et al. [20])

microorganisms are called antimicrobial agents. These anti-microbial agents are classified according to their role of effect against the microorganisms; biostatic agents stop the growth of the microorganisms there by allowing body's defense mechanism to eliminate them. There are germicides that kill the organisms affect application. These germicides may exhibit selective toxicity that is they may have effect against viruses (viricides), bacteria (bacteriocides), algae (algicides) or fungi (fungicides) [31]. Nature has been a source of medicinal agents, including all types of living organisms, for thousands of years with various energy sources of phytochemicals showing good action in controlling microbes [8,32]. Many phytochemical studies have been conducted in Brazil and India [33]. A study has shown that antimicrobial activity as well as cell toxicity of extracts from plant species against some bacteria and fungi has indicated that ethanol extracts from the plant species were toxic to the cells and only on species of the plants produced antimicrobial activity [8]. The antimicrobial potentials of plants have been tested by researchers worldwide especially Latin America where plants species are abundant. In Argentina, 122 plants species used for herbal medication were investigated and tested [33]. There has been a revival of interest in herbal medicines, to control major diseases and the need to discover new molecular structures as lead compounds. The healing activity may be slow with the use of plant extracts but have permanent cure against various diseases [6]. Antibacterial agents are classified into three categories; antibiotics (chemically synthesized), non-antibiotic and immunological products. These antimicrobial agents use actions against the microbes which are to target the microbe cell and disrupt; cell-wall synthesis, protein synthesis, nucleic acid synthesis, enzymatic activity, folate metabolism

or damage cytoplasmic membrane [31]. Yemeni traditional healer's uses ethanol extracts of 20 plants species for the treatment of pathogenic diseases. Both gram positive and gram negative bacteria used for the antibacterial screening of different plant species. Among all the plant species tested, *L. inermis* ethyl acetate extract was showed highest antibacterial activity [26] Dama et al. [34] studied quinonic compounds from *L. inermis* in-vitro for antimicrobial properties. Kirkland and Marzin [35] conducted genotoxic studies on lawsone and suggested that it is a weak bacterial mutagen for *Salmonella typhimurium* strain TA98 and was more clearly mutagenic for strain TA2637. Overall, it is suggested that *L. inermis* possess no genotoxic risk to the consumer. Antibacterial effect was also reported by the aqueous extract of leaves of *L. inermis* [36]. Aqueous, methanol and chloroform crude extracts of *L. inermis* leaves showed the in-vitro antimicrobial activity by inhibiting the growth of different strains of pathogenic bacteria [37].

*Salmonella typhi*: Firstly, *Salmonella* infection of man and animals continues to be a distressing health problem worldwide. Far from disappearing, the incidence in developing countries has risen higher than expected. *Salmonella* are widely dispersed in nature, including the gastrointestinal tracts of domesticated and wild mammals, reptiles, birds, and insects with over 2,500 serotypes as defined by the somatic and flagellar antigens. Some *Salmonella* serotypes, such as typhi and paratyphi are highly adapted to humans and have no other known natural hosts. Others, such as typhimurium [38] and enteritidis, have a broad host range and can infect a wide variety of animal hosts. These non-typhoid *Salmonella* can cause protean manifestations in humans, including acute gastroenteritis, bacteremia, and

extraintestinal localized infections involving many organs. The widespread distribution of *Salmonella* in the environment, their increasing prevalence in the global food chain, [39] and their virulence and adaptability result in an enormous medical, public health, and economic impact worldwide [40]. *Salmonella typhi* is a gram-negative enteric bacillus belongs to the family Enterobacteriaceae, a motile, facultative anaerobe that is susceptible to various antibiotics. According to World Health Organization (WHO), typhoid fever can be an issue in areas with overcrowding and poor hygiene where transmission is oral-fecal usually by ingestion of contaminated food and/or water [41]. Generally the incubation period ranges between 3 to 60 days with an average of 8 to 14 days. This period depends on the quantity of inoculum and host factors. The clinical presentation of typhoid fever can be nonspecific ranging from mild symptoms (such as low grade fever, malaise, headache, and dry cough), to severe abdominal pain, intestinal perforation and neurologic manifestations. It can therefore resemble other diseases that are common in areas where typhoid fever is endemic, such as malaria, pneumonia, and tuberculosis and treatment consists of antibiotics, mostly fluoroquinolones or cephalosporins (according to antibiotic susceptibility), antipyretics, and individualized supportive therapy based on the patient's presentation [42].

**Escherichia coli:** *Escherichia coli* is a gram-negative, facultative anaerobic, rod-shaped, coliform bacterium of the genus *Escherichia* that is commonly found in the lower intestine of warm-blooded organisms (endotherms) [43]. *E. coli* is a type of bacteria that normally lives in human intestines and in the gut of some animals which can cause diarrhea as a result of eating contaminated food or water while many associate it with food poisoning. However, some types of *E. coli*, particularly *E. coli* O157:H7 can cause intestinal infection. In fact, 75% to 95% of urinary tract infections are caused by *E. coli*. *E. coli* is a normal resident of the bowel, which is how it makes its way to the urinary tract [44, 45]. Most *E. coli* strains do not cause disease, naturally living in the gut, but virulent strains can cause gastroenteritis, urinary tract infections, neonatal meningitis, hemorrhagic colitis, and Crohn's disease. Common signs and symptoms include severe abdominal cramps, diarrhea, hemorrhagic colitis, vomiting, and sometimes fever. In rare cases, virulent strains are also responsible for bowel necrosis (tissue death) and

perforation without progressing to hemolytic-uremic syndrome, peritonitis, mastitis, sepsis, and gram-negative pneumonia; however, healthy individuals of all ages are at risk to the severe consequences that may arise as a result of being infected with *E. coli* and the rate and severity of infections are higher among children under the age of five, including as many as 380,000 deaths annually [46,47]. The mainstay of treatment is the assessment of dehydration and replacement of fluid and electrolytes. Administration of antibiotics has been shown to shorten the course of illness and duration of excretion of enterotoxigenic. The antibiotic used depends upon susceptibility patterns in the particular geographical region. Currently, the antibiotics of choice are fluoroquinolones or azithromycin, with an emerging role for rifaximin [48,49].

**Shigella:** Shigellosis is a bacterial infection that affects the digestive system which is spread through contaminated water and food or through contact with contaminated feces. The bacteria release toxins that irritate the intestines and cause an infection known as shigellosis with the primary symptom of diarrhea, fever, and stomach cramps usually begin 1–2 days after infection and last 7 days. Most people recover without needing antibiotics, however, people with severe illness and those with underlying conditions that weaken the immune system are given antibiotics to shorten the duration of illness (by about 2 days) and might help reduce the spread of infection to others. Personal hygiene measures can help protect one from the infection. *Shigella* is a genus of bacteria that is Gram-negative, facultative anaerobic, non-spore-forming, nonmotile, rod-shaped and closely related to *E. coli*. The genus is named after Kiyoshi Shiga, who first discovered it in 1897 with natural habitat in humans and gorillas and causes diseases in primates [50,51]. *Shigella* is one of the leading bacterial causes of diarrhea worldwide, causing an estimated 80–165 million cases. The number of deaths it causes each year is estimated at between 74,000 and 600,000 [52,53]. Contacting the healthcare provider or facility is a major way of control, drinking plenty of fluids to prevent dehydration, ciprofloxacin and azithromycin are recommended as oral antibiotics can shorten the time of fever and diarrhea by about 2 days [54].

### 1.3 Statement of Problem

The complexity of available drugs, the resistances of microorganisms and finances to treat diseases in developing countries especially

in resource limited settings is been on the rise due to the increase in standard of living and increase in the cost of health care to tackle diseases and the organisms causing these diseases. Lack of information to individuals living in areas with available plants with antimicrobial properties is a principal challenge. Thus, the antimicrobial action of the plant extracts of Lawsonia inermis (Henna) against Salmonella typhi, Shigella spp., and Escherichia coli will confine for the resolution and treatment of these infectious microorganisms while the enlightenment of the individuals in these localities will be achieved. The study therefore, aimed to ascertain and investigate the antimicrobial activity of Lawsonia inermis (Henna) leave extract against Salmonella typhi, Shigella spp., and Escherichia coli.

#### 1.4 Significance of Study

Investigating the antimicrobial activity of Lawsonia inermis extracts on Salmonella typhi, Shigella, and Escherichia coli as infections and diseases of medical importance in humans, will aid in the treatment of such infections and diseases in the simplest, effective and cost effective extracts of the plant. About 80% of developing countries, citizens used traditional medicine based on plant products [55]. Thus, this study will improve the standard of living of individuals living in developing countries where the plant species are available. Also, the availability of Lawsonia inermis will add to the pool of knowledge to the resource limiting settings and in the identification of naturally antimicrobials which may be potentially used in the production of new clinical drugs by the pharmaceutical industries.

## 2. MATERIALS AND METHODS

**Study Area:** The study was carried out at the College of Research and Technology, Shaheed Udham Singh Group of Institutions. The college is located in Tangori town, Mohali region, Punjab. The region has 4 weather seasons, winter, spring, summer and fall. The university covers a landmass of 100 square meters and is located at latitude 30.589055, longitude 76.704130, it is found 11 miles away from Chandigarh the state capital of Punjabi.

**Sample Collection:** Henna leaves; The Lawsonia inermis leaves powder was obtained from Nupur Company that produces the powder for hair dye (a100% henna). Microorganism; the test

microorganisms were obtained from sewage water from the environment. The target organisms, E. coli S. typhi and Shigella were obtained by performing serial dilution, culture streaking for pure isolation on nutrient broth and agar respectively.

### 2.1 Preparation of Extracts

**Macerate:** The Henna powder used was measured (150g) by inserting it in a container with a solvent (50ml Ethanol) and allowed to stand at room temperature for a period of minimum 3 days with frequent agitation. The mixture was thereafter filtered using the Whatman's No 1 filter paper [56].

**Soaking:** The extract powder was measured (50g), soaked in 150 ml of solvent (Ethanol) in a 500 ml sterile conical flask and covered with cotton wool. It was then plugged and wrapped with aluminum foil and vigorously shaken. The mixture was left to stand overnight (24 h) in a shaking water bath at 40°C. The mixture was then filtered using a Whatman's No. 1 filter paper [57].

**Boiling:** The Henna powder measured (50g), meshed and placed in a container containing 150ml of Ethanol (solvent), boiled for 30minutes with constant stirring, allowed to cool and it was filtered [58].

**Preparation of Agar:** The agar was measured according to the required quantity of water and producers instructions. The agar mixture is sterilized in a flask in the autoclave at 121°C for 15 min at 15 pounds per square inch (psi) and cooled to 40 - 50°C was poured aseptically, in the volume of 20ml each, into sterilized Petri dishes and allowed to harden under room temperature. The plates were placed in the incubator for 24h at 37°C to check for its sterility prior to antimicrobial test [59].

**Preparation of McFarland Standard:** The turbidity standard equivalent to 0.5 McFarland standards was prepared by adding 1ml of concentrated tetraoxosulphate (VI) acid to 99ml of water. 0.5g of dehydrate barium chloride was dissolved in 50ml of distilled water. After which 0.6ml of the barium chloride solution was added to 99.4ml of the acid solution. The mixture was mixed properly and a small portion of the turbid solution was transferred into a corked tube and stored properly at room temperature ready for use [59].

**Determination of Antimicrobial Activity:** The test organisms were each streaked and spread on the surface of the prepared nutrient agar medium. The inoculated plates were allowed for 30min at room temperature for the organisms to pre-diffuse. After which, the inoculated plates were punched with a 5mm cork borer to make wells in the agar plate. The wells were each filled with the different plant extracts aseptically and the plates were incubated at 37°C for 24h. The antibacterial activity of the active constituents of the plant extracts were tested on each of the test organisms and were determined by measuring inhibition zone diameter (IZD) in millimeters (mm) [59].

## 2.2 Data Analysis

The results obtained from the antibacterial assay were analyzed using descriptive statistics and one way Analysis of variance (ANOVA) tests. The experimental design used was completely randomized design.

## 3. RESULTS AND DISCUSSION

Amos et al. and Rayavarapu et al. reported a significant evaluation of plant materials to provide a major source of natural therapeutic remedies used for antimicrobial properties against aqua pathogenic bacteria and fungi [59,8]. In this study, the antimicrobial activity of ethanoic extract of *Lawsonia inermis* was verified against *S. typhi*, *E. coli* and *Shigella*.

In Table 1, the inhibition zones upon the application of soaked ethanoic extracts revealed the highest inhibition zone of 19.50mm in *Shigella* spp isolated culture. The lowest inhibition zone was at 5.00mm of the isolate *E. coli* upon the application of the Boiled ethanoic extract, and of the isolate *Shigella* with the application of Boiled ethanoic extract.

In Table 2, the mean zones of inhibition (mm) observed upon the introduction of ethanoic extracts of *Lawsonia inermis* to bacterial isolates shows the highest mean of inhibition zone obtained was 19.5mm from application of soaked ethanoic extracts of *Lawsonia inermis* to *Shigella*. The lowest inhibition zone observed was 5.00mm of produced to *E. coli*.

The result achieved from Tables 1 and 2 shows that the soaked ethanoic extract inhibited the growth of test organisms *S. typhi*, *E. coli* and *Shigella*, with *S. typhi* and *Shigella* having a high

susceptibility than *E. coli* which has a lower susceptibility range. The macerated ethanoic extract had a low susceptibility effect against *S. typhi* and *E. coli* with a medium to high sensitivity towards the isolate *Shigella*. The boiled ethanoic extract had no inhibitory effect against *E. coli* with a medium inhibitory effect against *S. typhi* and *Shigella* isolates. Maceration at an elevated temperature (50°C) increases the extraction efficiency and have a stronger antimicrobial effect. The plant leaves powder of *Lawsonia inermis* is shown to have varying active components that are release into the solvents through various methods of extraction. Therefore for its use against certain confirmed organisms, a particular method of extraction is employed to achieve a better antimicrobial effect.

In table 3, the mean zones of inhibition of bacterial isolates upon the introduction of control antibiotics (Gentamicin, Ciprofloxacin and Cefataxime) used for *Shigella* spp, *E. coli* and *S. typhi* respectively. The highest mean zone of inhibition of antibiotics is 26.00mm observed from Gentamicin upon its application on *Shigella*. The lowest mean zone of inhibition is 18.00mm obtained from Cefataxime upon its introduction on *Salmonella*.

The result from table 3 indicated that the zones of inhibition for each of the controls used in the antibacterial assay had Ciprofloxacin producing inhibitory zone ranging from 20-22 mm, Cefataxime produced zones of inhibition ranging from 18-20 mm, and Gentamicin produced zones of inhibition ranging from 25-26mm. Cefataxime shows to have the lowest zone of inhibition against *S. typhi*, while Gentamicin had the highest zone of inhibition against *Shigella*. The table indicates that the test organisms are sensitive to the antibiotics used against them as controls. Using the analysis ANOVA, the data supports that there is no difference in the ranges of effect of antibiotics against each of the organisms (at  $p < 0.05$ ,  $F_{Cal} = 0.208$ ,  $F_{Tab} = 5.1433$ ; at  $p < 0.01$ ,  $F_{Tab} = 10.925$ ). At both confidences,  $F_{Cal}$  is less than  $F_{tab}$  and therefore the  $H_0$  is accepted.

In the result section (Table 4), it was shown that there was no significant difference between the zones of inhibition produced by the controls and Ethanoic extract of *Lawsonia inermis* (at  $p < 0.05$ ,  $F_{Cal} = 4.201$ ,  $F_{Tab} = 4.066$ ) and thus indicating that the usage of ethanoic extracts of *Lawsonia inermis* has a relatively close effect to the

antibiotics used as control. This indicates that the ethanoic extracts have a probability of providing similar effects against target microorganisms at  $p < 0.01$ ,  $F_{Cal} = 4.201$ ,  $F_{Tab} = 7.591$  when used as treatment. However, a longer period of usage of the ethanoic extracts may be required to obtain a desired effect of inhibition on the target organisms.

This study has indicated that the extraction of the active components of *Lawsonia inermis* through ethanoic extraction has improved the release of active compound into the solvent and provides a better concentration of the active compounds to produce inhibitory effects against targeted

microorganisms. It is shown that the different extraction methods obtained a better concentration of active compounds which shows a medium inhibitory effect against the targeted microorganisms.

The Statistical analysis were applied to the result Tables 2,3 and 4 using the one way ANOVA test to compare the differences in the means indicated that there was no significant difference in the effects of the ethanoic extracts of *Lawsonia inermis* on the tests organisms *S. typhi*, *E. coli* and *Shigella*. ( $p < 0.05$ ,  $F_{Cal} = 0.103$ ,  $F_{Tab} = 4.257$ ) as compared with the control drugs.

**Table 1. Zones of Inhibition (mm) on Cultures of *S. typhi*, *E. coli* and *Shigella* upon the application of ethanoic extracts of *Lawsonia inermis***

Test Organisms	Extracts					
	Soaked (mm)*		Macerated (mm)		Boiled (mm)	
<i>Escherichia. coli</i>	8.25	6.25	7.75	5.5	5	5
<i>Salmonella. typhi</i>	10.5	8.5	7.75	8.75	11	12.25
<i>Shigella</i>	19.5	19.5	16	15.5	5	20.25

\*millimeters (mm)

**Table 2. Mean Zones of Inhibition (mm) on the Cultures of *S. typhi*, *E. coli* and *Shigella* upon the application of ethanoic extracts of *Lawsonia inermis***

Test Organisms	Extract		
	Soaked (mm)	Macerated (mm)*	Boiled (mm)
<i>Escherichia. Coli</i>	7.25	6.63	5
<i>Salmonella typhi</i>	9.5	8.25	11.63
<i>Shigella</i>	19.5	15.75	12.63

\*millimeters (mm)

**Table 3. Mean Zones of Inhibition (mm) on cultures of *S. typhi*, *E. coli* and *Shigella* upon the application of control antibiotics**

Test Microorganism	Extract			
	Antibiotics	Soaked (mm)	Macerated (mm)	Boiled (mm)*
<i>Escherichia. Coli</i>	Ciprofloxacin	20	22	21
<i>Salmonella typhi</i>	Cefataxime	19	21	18
<i>Shigella</i>	Gentamicin	25	26	26

\*millimeters (mm)

**Table 4. Mean Zones of Inhibition (mm) on cultures of *S. typhi*, *E. coli* and *Shigella* upon the application of ethanoic extracts of *Lawsonia inermis* and control antibiotics**

Test Organisms	Extracts and Antibiotics				
	Soaked (mm)	Macerated (mm)	Boiled (mm)	Antibiotics (mm)*	
<i>Escherichia. coli</i>	7.25	6.63	5	21	
<i>Salmonella typhi</i>	9.5	8.25	11.63	19.3	
<i>Shigella</i>	19.5	15.75	12.63	25.7	

\*millimeters (mm)



#### 4. CONCLUSION

The resulting effect of this study paved a way in the antimicrobial potential of Lawsonia inermis ethanoic extracts against *S. typhi*, *E. coli* and *Shigella* which indicated that the extracts of Lawsonia inermis has active compounds that have antimicrobial effect against the test bacteria and can be useful in their treatment.

#### 5. RECOMMENDATION

The discovery of new novel drugs enhances the connection between traditional medical practitioner's reports and modern medicine reports to develop more active, stable and efficient drugs as suggestions to the unlimited potential of Lawsonia inermis plant. However, this ancient concept should be carefully evaluated in the light of modern medical practices and can be utilized fully or partially if found suitable.

Based on the results obtained from this research, the following recommendations are made

1. The ethanoic extracts are to be explored from its effect against other microorganisms and human consumption.
2. The development of efficient extraction method is to be acquired to obtain or exploits the plants potential rather than the traditional methods of extraction and
3. The development of better chemicals or solvents to harvest the desired active compounds should be explored.

#### DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

#### ACKNOWLEDGEMENTS

Authors wish to acknowledge and appreciate the support and contribution of Prof and Mrs Amos Bassi. Our immense pleasure goes to Mrs Jasmeet Kaur for timely providing all the facilities and motivation in the completion of experimental

work. We are also thankful to all the staff of the Technical Department, SUS College of research and technology, Tangori, for their kind assistance and co-operation in the laboratory.

#### COMPETING INTERESTS

Authors have declared that no competing interests exist.

#### REFERENCE

1. Dahake PR, Kamble SI. Study on Antimicrobial Potential and Preliminary Phytochemical Screening of Lawsonia Inermis Linn. Int J Pharm Sci Res. 2015;6(8):3344-50. DOI:10.13040/IJPSR.0975-8232.6(8).3344-50.
2. Agarwal P, Alok S, Verma A. An update on Ayurvedic herb henna (*Lawsonia inermis* L.): A review. Int J Pharm Sci Res; 2014;5(2): 330-39. DOI: 10.13040/IJPSR.0975-8232.
3. Goyal BR, Goyal RK, Mehta AA. Phyto-Pharmacognosy of *Archyranthes aspera*: A Review. Pharmacog Rev. 2008;1:1.
4. Rimawi M, Mahmoud al masri, Nedaa' Husein, Arwa N T al-hinnawi., Ola al masimi. Lena sabrah. Natural Antimicrobial Activity of Lawsonia inermis and Indigo tinctoria against clinically isolated Microorganisms. International Journal of Pharmacy and Pharmaceutical Sciences. 2018;10(1):191-194.
5. Kasture SB, Une HD, Sarveiyal VP, Pal SC: Nootropic and anxiolytic activity of saponins of *Albizia lebeck* leaves. Pharmacology, Biochemistry and Behavior; 2001;69: 439-444.
6. Kaladhar D, Narasinga VR, Sreenu B, Harasreeramulu S. Comparative antimicrobial studies of *Dioscorea hamiltonii* hook.f. tubers with *Azadirachta indica* stem, JPST. 2010;2(8):284-87.
7. Kamal M, Jawaid T. Pharmacological Activities of Lawsonia inermis Linn: A Review. International Journal of Biomedical Research. 2015;1(2):62- 68.
8. Rayavarapu KA, Kaladhar D, Santosh Kumar S. Evaluation of antimicrobial activity of Lawsonia Inermis (Henna) on aquapathogens. Journal of Pharmaceutical and Biomedical Sciences. 2011;7:02. ISSN NO- 2230 – 7885.
9. Alan TB, Alan CW, Michael G. Search and discovery strategies for biotechnology: the

- paradigm shift. *Microbiology and Molecular Biology Reviews*; 2000;64(3): 573-06.
10. Faidon M, Fotini A, Antonis Z. Organic food: buying more safety or just peace of mind, A critical review of the literature. *Critical Reviews in Food Science and Nutrition*. 2006;46:23–56.
  11. Gislene G, Nascimento F, Juliana L, Paulo C, Freita., Giuliana LS. Antibacterial activity of plant extracts and phytochemicals on antibiotic resistant bacteria. *Brazilian Journal of Microbiology*. 2000;31:247-56.
  12. Chitme HR, Chandra R, Kaushik S. Studies on anti-diarrheal activity of *Calotropis gigantea* R.Br. in experimental animals. *Journal of Pharmacy and Pharmaceutical Sciences*. 2003;7:70-75.
  13. Gaherwal S, Johar F, Wast N, Prakash M. Anti-Bacterial Activities of *Allium sativum* Against *Escherichia coli*, *Salmonella* Ser. Typhi and *Staphylococcus aureus*. *International Journal of Microbiological Research*. 2014;5(1): 19-22. ISSN 2079-2093. DOI: 10.5829/idosi.ijmr.2014.5.1.82100.
  14. Kim HS. Do not put too much value on conventional medicines. *Journal of Ethnopharmacology*, 2005;100(1-2):37-39.
  15. Abdelraouf A, Amany A, Alyazji, Nedaa A. Antibacterial, Antifungal and Synergistic Effect of *Lawsonia inermis*, *Punica granatum* and *Hibiscus sabdariffa*. *Annals of Alquds Medicine* 2011;(7):33-41.
  16. Gibbons LG, Gopalla NG, Hunter RH, Kerr AK, Mulrey PM. *Plants encyclopedia*. First American Edition, US. 2004;232.
  17. Timir B Patel, Dharmesh K, Golwala, Santosh Kumar Vaidya. Assessment of Potential Antiulcer activities of Methanolic Extracts of *Lawsonia inermis* Linn. *Bark. Aegaeum Journal* 2020;8(4): 95-99.
  18. Sarita S., Sujeet G., Bhumika Y. *Inermis* A Review Article on *Lawsonia*. *World Journal of Pharmaceutical Research*. 2020;9(11): 490-505.
  19. Jeba Sweetly Dharmadhas, Issac Abraham Sybiya, Vasantha Packiavathy, Jeyapragash Danaraj, Sumayya Rehaman, Aasaithambi Kalaiselvi. Preliminary Studies On Phytochemicals And Antimicrobial Activity Of Solvent Extracts Of Medicinal Plant *Lawsonia Inermis*. *Int. J. Adv. Res.* 2019;7(10):887-896.
  20. Chang CH, Ling HY, Chang CY, Liu YC. Comparisons on the antioxidant properties of fresh, freeze-dried and hot-air dried tomatoes. *Journal of Food Engineering*. 2006;77:478 –85.
  21. Kawo AH, Kwa AM. Phytochemical screening and antibacterial activity of the aqueous extracts and fractions of ethanolic extracts of *Lawsonia inermis*. *International Research Journal of Microbiology*. 2011; 2(12):510-516.
  22. Krishnaiah D, Sarbatly R, Bono A. Phytochemical antioxidants for health and medicine: A move towards nature. *Biotechnol Mol Biol Rev*. 2007;1:97-104.
  23. Saidulu C, Venkateshwar Rao, SG. Preliminary Phytochemical Studies of Medicinal Plant Drug: *Withania Somnifera* Linn'. *Biolife*. 2014;2(1):306-312.
  24. Oda Y, Nakashima S, Kondo E, Nakamura S, Yano M, Kubota C. Comparison of lawsone contents among *Lawsonia inermis* plant parts and neurite outgrowth accelerators from branches. *J Nat Med*. 2018;72:890-6.
  25. Ali-Esmail Al-Snafi. A Review on *Lawsonia Inermis*: A Potential Medicinal Plant. *Int J Curr Pharm Res*. 2019;11(5):1-13. DOI:<http://dx.doi.org/10.22159/ijcpr.2019v11i5.35695>.
  26. Sharma RK, Goel A, Bhatia AK. *Lawsonia inermis* linn: A plant with cosmetic and medical benefits. *Int J Appl Sci Biotechnol*. 2016;4(1):15-20. DOI: 10.3126/ijasbt.v4i1.14728
  27. Huang YC, Hung WC, Kang WY, Chen WT, Chai CY, *Toxicol. Lett*. 2007;170:116-12.
  28. Ritesh Kumar Sharma, Anjana Goel, Bhatia AK. *Lawsonia inermis* Linn: A Plant With Cosmetic and Medical Benefits. *Int J Appl Sci Biotechnol*. 2016;4(1):15-20.
  29. Amit SB., Babasaheb NK, Rajkumar VS. A phytopharmacological review on *Lawsonia inermis* (Linn.). *Int. J. of Pharm. & Life Sci.(IJPLS)*. 2011;2(1):536-541-536
  30. Vali L, Stefanovits E, Szentmihalyi K, Febel H, Sardi E, Lugasi A, Kocsis I, Blazovics A. Liver-protecting effects of table beet (*Beta vulgaris var. Rubra*) during ischemia-reperfusion. *Nutrition*. 2007;23: 172–178.
  31. Alviano DS, Alviano CS. Plant extracts: Search for new alternatives to treat microbial diseases. *Current Pharmaceutical Biotechnology*. 2009;10(1): 106-121.
  32. Amit S, Sonal S, Uzma R, Shilpa R, Amla B. Broad-spectrum antimicrobial properties

- of medicinally important plant *Jatropha curcas* L. IJPSRR. 2010;4(3):11.
33. Jayakumari M, Maheswari K, Subashree M, Umamaheswari M, Mala P, Sevanthi T, Lakshmi S. Antibacterial potential of *Acalypha indica* against human pathogens. *International Journal of Current Research*. 2010;1:001-004.
  34. Dama LB, Poul BN, Jadhav BV. Antimicrobial activity of Naphthoquinonic compounds. *Journal of Ecotoxicology and Environmental Monitoring*. 1999;8:213-215.
  35. Kirkland D, Marzin D. An assessment of the genotoxicity of 2-hydroxy-1, 4-naphthoquinone, the natural dye ingredient of Henna. *Mutation Research*. 2003;537: 183-199.
  36. Baba-Moussa F, Nacoulma O, Ouattara A, Nguyen HP, Akpagana K, Bouchet P. Antibacterial activity of total aqueous extracts of *Combretum micranthum* *Lawsonia inermis* and *Waltheria indica* plants from west African pharmacopoeia. *Revue de Medecines et Pharmacopees Africaines*. 1997;11(12):197-203.
  37. Malekzadeh F. Antimicrobial activity of *Lawsonia inermis* L. *App Microbiol*. 1968;16(4):663-4.
  38. Dinesh Babu P, Subhasree RS. Antimicrobial Activities of *Lawsonia inermis* - A Review. *Academic Journal of Plant Sciences*. 2009;2(4):231-232.
  39. Cheng-Hsun C, Lin-Hui S. *Salmonella*, Non-Typhoidal Species (*S. Choleraesuis*, *S. Enteritidis*, *S. Hadar*, *S. Typhimurium*). *Antimicrobe*; 2010.
  40. World Health Organization. Background document: The diagnosis, treatment and prevention of typhoid fever; 2003. Retrieved:[http://apps.who.int/iris/bitstream/10665/68122/1/WHO\\_V-B\\_03.07\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/68122/1/WHO_V-B_03.07_eng.pdf).
  41. Nyirimanzi N, Rogo T. Fever of unknown origin in a family due to *Salmonella typhi*: A case report. *Rwanda Medical Journal*. 2016;73(4):12-15.
  42. Tenaillon O, Skurnik D, Picard B, Denamur E. The population genetics of commensal *Escherichia coli*". *Nature Reviews. Microbiology*. 2010;8(3):207–17. DOI:10.1038/nrmicro2298.
  43. Vogt RL, Dippold L. *Escherichia coli* O157: H7 outbreak associated with consumption of ground beef, June–July 2002". *Public Health Reports*. 2005;120(2):174–78. DOI:10.1177/003335490512000211.
  44. Tortora G. *Microbiology: An Introduction*. San Francisco, CA: Benjamin Cummings. 2010;85–87,161,165. ISBN 978-0-321-55007-1.
  45. Todar K. Pathogenic *E. coli*". Online Textbook of Bacteriology. University of Wisconsin–Madison Department of Bacteriology. Retrieved 30 November 2007.
  46. Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M, Finlay BB. Recent advances in understanding enteric pathogenic *Escherichia coli*". *Clinical Microbiology Reviews*. 2013;26(4):822–80. DOI:10.1128/CMR.00022-13.
  47. Al-Abri SS., Beeching NJ, Nye FJ. Traveller's diarrhoea. *The Lancet. Infectious Diseases*. 2005;5(6):349–60. DOI:10.1016/S1473-3099(05)70139-0.
  48. US Centers for Disease Control and Prevention. "Enterotoxigenic *E. coli* (ETEC)". Retrieved 21 July 2016.
  49. Yabuuchi E. "Bacillus dysentericus (sic) 1897 was the first taxonomic rather than *Bacillus dysenteriae* 1898". *International Journal of Systematic and Evolutionary Microbiology*. 2002;52 (Pt 3):1041. DOI:10.1099/00207713-52-3-1041.
  50. Ryan KJ, Ray CG. *Sherris medical microbiology: an introduction to infectious diseases 2004; (4th ed.)*. McGraw-Hill Professional Med/Tech. ISBN 978-0-8385-8529-0.
  51. Pond K. "Shigella". *Water recreation and disease. Plausibility of associated infections: Acute effects, sequelae and mortality*. WHO. 2000;113–8.
  52. Bowen A. "Chapter 3: Infectious Diseases Related to Travel". *The Yellow Book: Health Information for International Travel*. CDC; 2016. ISBN 978-0-19-937915-6. Retrieved 22 June 2016
  53. Mims C, Dockrell H, Goering R, Roitt I, Wakelin D, Zuckerman M. *Medical Microbiology*. 2004;(3rd ed.). Mosby:287.
  54. Center for Disease Control and Prevention (CDC) *Shigella- Shigellosis*; 2020. Retrieved 9th April 2021; Available:<https://www.cdc.gov/shigella/diagnosis/treatment.html>
  55. Makanjuola Y, Dada E, Akharaiyi F. Antibacterial Potentials of *Parquetina nigrescens* extracts on Some Selected

- Pathogenic Bacteria. Journal of Natural Products. 2010;3:124-129.
56. Azwanida N. A Review on the Extraction Methods Use in Medicinal Plants, Principle, Strength and Limitation. Med Aromat Plants. 2015;4:196. DOI:10.4172/2167-0412.1000196.
57. El-Mahmood M. Antibacterial activity of crude extracts of Euphorbia hirta against some bacteria associated with enteric infections. Journal of Medicinal Plants Research. 2009;3(7):498-505.
58. Goyal P, Khanna A, Abhisek C, Chauhan G, Kaushik P. In vitro evaluation of crude extracts of Catharanthus roseus for Potential Antibacterial Activity. International Journal of Green Pharmacy. 2008;2(3):176-181.
59. Amos D, Idris A, Bibiana N. Preliminary evaluation of antibacterial potential of four common Nigerian plants against isolates of Staphylococcus aureus and Escherichia coli. New York Science Journal. 2016; 9(6):67-71.

© 2022 Bassi et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*

*The peer review history for this paper can be accessed here:*  
<https://www.sdiarticle5.com/review-history/81490>